Matthew Goetz

Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. Professor of Oncology and Pharmacology Tweets are my own

[Journal of Clinical Oncology @JCO_ASCO]

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer. Co-authored by @GraceChoongMD, @DrJudyBoughey, and @mpgoetz
#BreastCancer #bcsm

Read more. https://t.co/vgKxWWdQOZ

[Jasmine Kamboj, MD, FASCO @JasmineKambojMD]

@rleonferre @mpgoetz @MayoClinic @MayoCancerCare @MayoHemeOnc @oncodaily @OncBrothers @OncLive @IMG_Oncologists @StoriesImg
#breastcancer #twincities
Excellent line up of speakers; MInnesota, plz register for the presentation next week- April 10.

[Matthew Goetz @mpgoetz]

The ki-67 response rate (4 week Ki<=10%) was 86% in 22 patients. We are now ready to move this to the randomized portion comparing endoxifen with AI+ OFS

[Matthew Goetz @mpgoetz]

Excited to present the initial findings of the pk run-in of neoadjuvant Z-endoxifen in premenopausal women at the annual SABCS meeting

[Matthew Goetz @mpgoetz]

Congratulations to Dr. Roberto Leon Ferre for your ASCO Conquer Cancer Advanced Clinical Research Award.

[Matthew Goetz @mpgoetz]

Bottom line, ET omission in this group is associated with a 25% increased risk of death with a median follow-up of 3 years.

[Matthew Goetz @mpgoetz]

What is the impact of endocrine therapy omission in ER low (IHC 1-10%) breast cancer? Dr. Grace Choong presents data at ASCO 2024 regarding the detrimental impact of ET omission in this group of pts with tumors traditionally characterized as biologically similar to TNBC

[Roberto Leon-Ferre @rleonferre]

📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in @JAMA_current

https://t.co/N0fMyRWjP3

[Michigan Football @UMichFootball]

IT’S GREAT TO BE A MICHIGAN WOLVERINE!

#GoBlue

[Matthew Goetz @mpgoetz]

@CFBONFOX @UW_Football @UMichFootball Michigan

[Matthew Goetz @mpgoetz]

In premenopausal women with ER+/HER2- breast cancer, the neoadjuvant EVANGELINE trial is testing the hypothesis that dual targeting of ER and PKC beta will result in substantial anti tumor activity without the need for ovarian function suppression https://t.co/ljrKlYlqxg

[Matthew Goetz @mpgoetz]

Endoxifen is known to be a more potent inhibitor of ER alpha compared to tamoxifen.  Based on an unbiased proteomic screen, we identify protein kinase beta as a new endoxifen drug target, resulting in suppression of AKT signaling and apoptosis

https://t.co/AUP5TWQnat

[Matthew Goetz @mpgoetz]

@DrSGraff @OncoAlert @drsarahsam @StoverLab @ErikaHamilton9 @hoperugo @Annals_Oncology Look out SERDS. SERMS are making a comeback!

[Matthew Goetz @mpgoetz]

@CarlosArteagaMD @utswcancer Well done!

[Matthew Goetz @mpgoetz]

Jack Cuzick shows the benefit of anastrozole in IBIS -II according to baseline estradiol levels at the SABCS McGuire lecture. Potentially practice changing.

[Judy Boughey @DrJudyBoughey]

@ALLIANCE_org plenary session. New group chair Dr Eva Galanis @MayoCancerCare opens the plenary session.

[Matthew Goetz @mpgoetz]

@UChicagoHemOnc @DrSGraff @RitaNandaMD @DorisDukeFdn @UChicagoMed Rita: Congratulations!

[Matthew Goetz @mpgoetz]

It was a pleasure to present these data. Critically important, as any biomarker needs to be fully validated before being used to select patients. In this case, these biomarkers are prognostic but clearly not predictive of abemacicib benefit.

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

Consistent invasive disease free survival benefit of adjuvant abemaciclib in #MonarchE regardless of ER, PR or Ki-67 expression. #ESMO23 @OncoAlert